Analysis of the Clinical Efficacy of Osimertinib Combined with Pemetrexed,Cisplatin,and Angiogenesis Inhibitors in Treating EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Objective To analyze the clinical value of osimertinib combined with pemetrexed,cisplatin,and angiogenesis inhibitors in the treatment of advanced non-small cell lung cancer(NSCLC)with positive epidermal growth factor receptor(EGFR)mutations.Methods A retrospective analysis was conducted on 62 patients with EGFR mutation-positive advanced NSCLC admitted to Nanyang Yuxi Jianhe Hospital from February 2020 to December 2023.Based on different treatment regimens,patients were divided into Group A(osimertinib+pemetrexed+cisplatin)and Group B(osimertinib+pemetrexed+cisplatin+angiogenesis inhibitors),with 31 patients in each group.The treatment outcomes,angiogenesis indicators,T lymphocyte subsets,serum tumor markers,and safety were compared between the two groups.Results The treatment efficacy rate(45.16%)and disease control rate(70.97%)in Group B were significantly higher than those in Group A(19.35%and 38.71%,respectively)(P＜0.05).After treatment,levels of CD4+and the CD4+/CD8+ratio in Group B were higher than those in Group A,while CD8+,vascular endothelial growth factor(VEGF),and thymidine kinase(TKl)levels were lower in Group B than in Group A,with significant differences(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The treatment regimen of osimertinib combined with pemetrexed,cisplatin,and angiogenesis inhibitors is effective and feasible for patients with EGFR mutation-positive advanced NSCLC.This combination not only effectively inhibits the tumor cells'ability to generate blood vessels but also enhances immune function with a high level of safety in medication use.
国家科技期刊平台
NSTL
万方数据
